1. Сергеев А.Ю., Сергеев Ю.В. Грибковые инфекции. Руководство для врачей. 2-е изд. М.: БИНОМ-Пресс, 2008. 
2. Сергеев А.Ю. Грибковые заболевания ногтей. 2-е изд. М.: Нацио­нальная академия микологии – Медицина для всех, 2007. 
3. Dixon DM, Polak A. In vitro and in vivo drug studies with three agents of central nervous system phaeohyphomycosis. Chemotherapy 1987; 33 (2): 129–40. 
4. Ryder NS. Specifi c inhibition of fungal sterol biosynthesis by SF 86–327, a new allylamine antimycotic agent. Antimicrob Agents Chemother 1985; 27 (2): 252–6. 
5. Ryder NS. Terbinafine: mode of action and properties of the squalene epoxidase inhibition. Br J Dermatol 1992; 126 (Suppl. 39): 2–7. 
6. Ryder NS, Dupont MC. Inhibition of squalene epoxidase by allylamine antimycotic compounds. A comparative study of the fungal and mam­malian enzymes. Biochem J 1985; 230 (3): 765–70. 
7. Suh DC, Shin H, Raut M, Tavakkol A. Usage patterns of medical ser­vices and prescription drugs in patients with tinea capitis. J Am Acad Dermatol 2004; 50: 86. 
8. Gupta AK, Sauder DN, Shear NH. Antifungal agents: an overview. Part II. J Am Acad Dermatol 1994; 30 (6): 911–33. 
9. Jensen JC. Clinical pharmacokinetics of terbinafine (Lamisil). Clin Exp Dermatol 1989; 14 (2): 110–3. 
10. Humbert H, Cabiac MD, Denouel J, Kirkesseli S. Pharmacokinetics of terbinafine and of its five main metabolites in plasma and urine, fol­lowing a single oral dose in healthy subjects. Biopharm Drug Dispos 1995; 16 (8): 685–94. 
11. Petranyi G, Meingassner JG, Mieth H. Activity of terbinafine in exper­imental fungal infections of laboratory animals. Antimicrob Agents Chemother 1987; 31 (10): 1558–61. 
12. Farag A, Taha M, Halim S. One-week therapy with oral terbinafine in cases of tinea cruris/corporis. Br J Dermatol 1994; 131 (5): 684–6. 
13. Cole GW, Stricklin G. A comparison of a new oral antifungal, terbinafine, with griseofulvin as therapy for tinea corporis. Arch Derma­tol 1989; 125 (11): 1537–9. 
14. del Palacio Hernandez A, Lopez Gomez S, Gonzalez Lastra F et al. A comparative double-blind study of terbinafine (Lamisil) and griseofulvin in tinea corporis and tinea cruris. Clin Exp Dermatol 1990; 15 (3): 210–6. 
15. Voravutinon V. Oral treatment of tinea corporis and tinea cruris with terbinafine and griseofulvin: a randomized double blind compar­ative study. J Med Assoc Thai 1993; 76 (7): 388–93. 
16. Baudraz-Rosselet F, Rakosi T, Wili PB, Kenzelmann R. Treatment 
17. Farkas B, Paul C, Dobozy A et al. Terbinafine (Lamisil) treatment of toenail onychomycosis in patients with insulin-dependent and non­insulin-dependent diabetes mellitus: a multicentre trial. Br J Dermatol 2002; 146 (2): 254–60. 
18. Goodfi eld MJ, Andrew L, Evans EG. Short term treatment of dermato­phyte onychomycosis with terbinafine. BMJ 1992; 304 (6835): 1151–4. 
19. Pollak R, Billstein SA. Efficacy of terbinafine for toenail onychomyco­sis. A multicenter trial of various treatment durations. J Am Podiatr Med Assoc 2001; 91 (3): 127–31. 
20. Watson A, Marley J, Ellis D, Williams T. Terbinafine in onychomycosis of the toenail: a novel treatment protocol. J Am Acad Dermatol 1995; 33 (5 Pt 1): 775–9. 
21. Zaias N, Serrano L. The successful treatment of finger Trichophyton rubrum onychomycosis with oral terbinafine. Clin Exp Dermatol 1989; 14 (2): 120–3. 
22. Friedlander SF, Aly R, Krafchik B et al. Terbinafine in the treatment of Trichophyton tinea capitis: a randomized, double-blind, parallel­group, duration-fi nding study. Pediatrics 2002; 109 (4): 602–7. 
23. Hamm H, Schwinn A, Brautigam M, Weidinger G. Short duration treatment with terbinafine for tinea capitis caused by Trichophyton or Microsporum species. The Study Group. Br J Dermatol 1999; 140 (3): 480–2. 
24. Nejjam F, Zagula M, Cabiac MD et al. Pilot study of terbinafine in children suffering from tinea capitis: evaluation of efficacy, safety and pharmacokinetics. Br J Dermatol 1995; 132 (1): 98–105. 
25. Haroon TS, Hussain I, Mahmood A et al. An open clinical pilot study of the efficacy and safety of oral terbinafine in dry non-infl ammatory tinea capitis. Br J Dermatol 1992; 126 (Suppl. 39): 47–50. 
26. Krafchik B, Pelletier J. An open study of tinea capitis in 50 children treated with a 2-week course of oral terbinafine. J Am Acad Dermatol 1999; 41 (1): 60–3. 
27. Aste N, Pau M. Tinea capitis caused by Microsporum canis treated with terbinafine. Mycoses 2004; 47 (9–10): 428–30. 
28. Koumantaki E, Kakourou T, Rallis E et al. Doubled dose of oral terbinafine is required for Microsporum canis tinea capitis. Pediatr Dermatol 2001; 18 (4): 339–42. 
29. Silm H, Karelson M. Terbinafine: efficacy and tolerability in young children with tinea capitis due to Microsporum canis. J Eur Acad Der­matol Venereol 2002; 16 (3): 228–30. 
30. Alvi KH, Iqbal N, Khan KA et al. A randomized double-blind trial of the efficacy and tolerability of terbinafine once daily compared to grise­ofulvin once daily in the treatment of tinea capitis. In: Shuster S, Jafary 40–6. Series. 1992; p. 35–40. 
31. Caceres-Rios H, Rueda M, Ballona R, Bustamante B. Comparison of terbinafine and griseofulvin in the treatment of tinea capitis. J Am Acad Dermatol 2000; 42 (1 Pt 1): 80–4. 
32. Fuller LC, Smith CH, Cerio R et al. A randomized comparison of 4 weeks of terbinafine vs 8 weeks of griseofulvin for the treatment of tinea capitis. Br J Dermatol 2001; 144 (2): 321–7. 
33. Lipozencic J, Skerlev M, Orofi no-Costa R et al. A randomized, dou­ble-blind, parallel-group, duration finding study of oral terbinafine and open-label, high-dose griseofulvin in children with tinea capitis due to Microsporum species. Br J Dermatol 2002; 146 (5): 816–23. 
34. Elewski BE, Caceres HW, DeLeon L et al. Terbinafine hydrochloride oral granules versus oral griseofulvin suspension in children with tinea capitis: results of two randomized, investigator-blinded, multicenter, international, controlled trials. J Am Acad Dermatol 2008; 59 (1): 41–54. 
35. Finlay AY. Global overview of Lamisil. Br J Dermatol 1994; 130 (Suppl. 43): 1–3. 
36. Pollak R, Billstein SA. Safety of oral terbinafine for toenail onychomy­cosis. J Am Podiatr Med Assoc 1997; 87 (12): 565–70. 
37. Villars V, Jones TC. Clinical efficacy and tolerability of terbinafine (Lamisil) – a new topical and systemic fungicidal drug for treatment of dermatomycoses. Clin Exp Dermatol 1989; 14 (2): 124–7. 
38. Abdel-Rahman SM, Herron J, Fallon-Friedlander S et al. Pharmaco­kinetics of terbinafine in young children treated for tinea capitis. Pedi­atr Infect Dis J 2005; 24 (10): 886–91. 
39. De Backer M, De Vroey C, Lesaffre E et al. Twelve weeks of continu­ous oral therapy for toenail onychomycosis caused by dermatophytes: a double-blind comparative trial of terbinafine 250 mg/day versus itraconazole 200 mg/day. J Am Acad Dermatol 1998; 38 (5 Pt 3): S57–63. 
40. Drake LA, Shear NH, Arlette JP et al. Oral terbinafine in the treat­ment of toenail onychomycosis: North American multicenter trial. J Am Acad Dermatol 1997; 37 (5 Pt 1): 740–5. 
41. Schopf R, Hettler O, Brautigam M et al. Efficacy and tolerability of terbinafine 1% topical solution used for 1 week compared with 4 weeks clotrimazole 1% topical solution in the treatment of interdigital tinea pedis: a randomized, double-blind, multi-centre, 8-week clinical trial. Mycoses 1999; 42 (5–6): 415–20. 

Ю.Б.Терехова, А.Ю.Миронов ММА им. И.Н.Сеченова